Naiyer A. Rizvi
YOU?
Author Swipe
View article: Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors
Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors Open
Purpose: Cergutuzumab amunaleukin (CA) is an immunocytokine comprising a variant form of interleukin-2 (constructed to avoid CD25 binding and Treg stimulation) fused to a carcinoembryonic antigen (CEA)-targeted antibody. This phase Ib open…
View article: 1345 Initial phase 1a/1b results of STK-012, an α/β IL-2 receptor biased partial agonist, with pembrolizumab, pemetrexed, and carboplatin in 1L PD-L1 negative non-squamous NSCLC
1345 Initial phase 1a/1b results of STK-012, an α/β IL-2 receptor biased partial agonist, with pembrolizumab, pemetrexed, and carboplatin in 1L PD-L1 negative non-squamous NSCLC Open
View article: 516 An open-label, phase II multicenter study of rituximab or tocilizumab for steroid-dependent or steroid-refractory immune-related adverse events due to immune checkpoint inhibitors
516 An open-label, phase II multicenter study of rituximab or tocilizumab for steroid-dependent or steroid-refractory immune-related adverse events due to immune checkpoint inhibitors Open
View article: Key considerations for advancing chimeric antigen receptor (CAR) T-cell therapy for systemic lupus erythematosus (SLE): a multi-partner/disciplinary working group perspective
Key considerations for advancing chimeric antigen receptor (CAR) T-cell therapy for systemic lupus erythematosus (SLE): a multi-partner/disciplinary working group perspective Open
Early data have shown the potential of chimeric antigen receptor (CAR) T-cell therapies to expand the therapeutic landscape in systemic lupus erythematosus (SLE). While many CAR T-cell therapy learnings can be drawn from the experience of …
View article: Mutational landscape of pure ductal carcinoma in situ and associations with disease prognosis and response to radiotherapy
Mutational landscape of pure ductal carcinoma in situ and associations with disease prognosis and response to radiotherapy Open
View article: Single-cell and spatial genomic landscape of non-small cell lung cancer brain metastases
Single-cell and spatial genomic landscape of non-small cell lung cancer brain metastases Open
View article: Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings
Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings Open
Introduction Neoadjuvant chemoimmunotherapy has achieved overall survival (OS) benefit for patients with resectable non-small cell lung cancer (NSCLC). Here, we present outcomes after 3 years of follow-up from the first reported study of n…
View article: 1325 T cell and immune activation from a phase 1 study of STK-012, a first-in-class IL-2R α/β selective partial agonist in advanced solid tumors
1325 T cell and immune activation from a phase 1 study of STK-012, a first-in-class IL-2R α/β selective partial agonist in advanced solid tumors Open
View article: Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab
Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab Open
View article: International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy
International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy Open
View article: Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development
Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development Open
The need for solid clinical definitions of resistance to programmed death 1 or its ligand (PD-(L)1) inhibitors for clinical trial design was identified as a priority by the Society for Immunotherapy of Cancer (SITC). Broad consensus effort…
View article: Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer Open
View article: Supplementary Data from Self-Renewing CD8<sup>+</sup> T-cell Abundance in Blood Associates with Response to Immunotherapy
Supplementary Data from Self-Renewing CD8<sup>+</sup> T-cell Abundance in Blood Associates with Response to Immunotherapy Open
Supplementary Figs. S1-S5
View article: Supplementary Data from Self-Renewing CD8<sup>+</sup> T-cell Abundance in Blood Associates with Response to Immunotherapy
Supplementary Data from Self-Renewing CD8<sup>+</sup> T-cell Abundance in Blood Associates with Response to Immunotherapy Open
Supplementary Figs. S1-S5
View article: Data from Self-Renewing CD8<sup>+</sup> T-cell Abundance in Blood Associates with Response to Immunotherapy
Data from Self-Renewing CD8<sup>+</sup> T-cell Abundance in Blood Associates with Response to Immunotherapy Open
Treatment with immune checkpoint blockade (ICB) often fails to elicit durable antitumor immunity. Recent studies suggest that ICB does not restore potency to terminally dysfunctional T cells, but instead drives proliferation and differenti…
View article: Data from Self-Renewing CD8<sup>+</sup> T-cell Abundance in Blood Associates with Response to Immunotherapy
Data from Self-Renewing CD8<sup>+</sup> T-cell Abundance in Blood Associates with Response to Immunotherapy Open
Treatment with immune checkpoint blockade (ICB) often fails to elicit durable antitumor immunity. Recent studies suggest that ICB does not restore potency to terminally dysfunctional T cells, but instead drives proliferation and differenti…
View article: Supplementary Data Figure S4 from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response
Supplementary Data Figure S4 from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response Open
Association of DAXX loss of function mutations and HLA-I LOH in tumor types with low rates of PD-L1 positivity and low TMB
View article: Supplementary Data Figure S2 from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response
Supplementary Data Figure S2 from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response Open
Somatic HLA-I LOH is associated with decreased durable clinical benefit and progression free survival in ICI-treated NSCLC
View article: Supplementary Data Table S3 from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response
Supplementary Data Table S3 from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response Open
EGFR and ALK mutations used for exclusion in the MSK clinical cohort
View article: Supplementary Data Figure S3 from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response
Supplementary Data Figure S3 from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response Open
Somatic HLA-I LOH is not significantly enriched in microsatellite instable samples
View article: Data from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response
Data from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response Open
Neoantigen presentation arises as a result of tumor-specific mutations and is a critical component of immune surveillance that can be abrogated by somatic LOH of the human leukocyte antigen class I (HLA-I) locus. To understand the role of …
View article: Supplementary Data Table S1 from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response
Supplementary Data Table S1 from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response Open
Characteristics of patients in the real-world clinico-genomic cohort
View article: Supplementary Data Figure S1 from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response
Supplementary Data Figure S1 from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response Open
HLA-I germline zygosity has no impact on patient survival in ICI-treated NSCLC
View article: Supplementary Data Figure S5 from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response
Supplementary Data Figure S5 from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response Open
Effects of hybridization on HLA baiting efficiency
View article: Supplementary Data Figure S2 from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response
Supplementary Data Figure S2 from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response Open
Somatic HLA-I LOH is associated with decreased durable clinical benefit and progression free survival in ICI-treated NSCLC
View article: Supplementary Data Table S3 from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response
Supplementary Data Table S3 from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response Open
EGFR and ALK mutations used for exclusion in the MSK clinical cohort
View article: Supplementary Data Table S1 from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response
Supplementary Data Table S1 from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response Open
Characteristics of patients in the real-world clinico-genomic cohort
View article: Data from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response
Data from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response Open
Neoantigen presentation arises as a result of tumor-specific mutations and is a critical component of immune surveillance that can be abrogated by somatic LOH of the human leukocyte antigen class I (HLA-I) locus. To understand the role of …
View article: Supplementary Data Figure S3 from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response
Supplementary Data Figure S3 from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response Open
Somatic HLA-I LOH is not significantly enriched in microsatellite instable samples
View article: Supplementary Data Figure S5 from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response
Supplementary Data Figure S5 from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response Open
Effects of hybridization on HLA baiting efficiency